Compare Summit Therapeutics Inc (SMMT) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Teradyne, Inc. — how do they compare? Summit Therapeutics Inc trades at $15.22 (market cap $12.06B), while Teradyne, Inc. trades at $402.87 (market cap $59.34B). The key difference: Teradyne, Inc. is far larger — about 4.9× Summit Therapeutics Inc's market cap, and Teradyne, Inc. pays a 0.14% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TER | |
|---|---|---|
Market Cap | $12.06B | $59.34B |
Sector | Health | Technology |
52-Week High | $26.98 | $483.84 |
52-Week Low | $12.55 | $109.30 |
Enterprise Value | $11.39B | $59.09B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Teradyne (TER) trades at $403.6, up 10.55% in 24 hours, near its 52-week high. The stock exhibits bullish technical signals with strong earnings beats in recent quarters, including Q2 2026 EPS of $2.47 versus $2.09 expected. Revenue growth is accelerating, driven by AI-led demand in semiconductor testing and robotics, with 2026 revenue projected at $4.5 billion. Valuation ratios are elevated, with a P/E of 52.14, reflecting high growth expectations.
The outlook remains positive due to robust AI-driven demand and record earnings, though high valuation poses a risk if growth slows. Analyst consensus is strongly bullish with a $481.63 price target. Key risks include execution challenges in scaling operations and sensitivity to semiconductor cycle downturns. Institutional buying, such as Anson Funds' purchase in Q1 2026, supports momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
